Clinical Trials Logo

Clinical Trial Summary

Glioblastoma (GBM) is the most aggressive and most frequent brain tumour. Approximately four people per 100,000 inhabitants are diagnosed with this disease every year. The standard treatment comprises surgical resection (whenever possible), normofractionated radiotherapy at a dose of 60Gray (Gy) and temozolomide (TMZ). Median overall survival in these patients is 14.6 months [13.2-16.8]. In a previous phase I clinical trial, dose escalation tolerance using simultaneous-integrated boost intensity-modulated radiation therapy (SIB-IMRT) technic has been evaluated. The investigator demonstrated that SIB-IMRT until a dose of 80Gy in 32 daily fractions, associated with TMZ is feasible and well tolerated by patients with glioblastoma. The aim of this present phase II clinical trial is to evaluate the overall survival at 18 months for patients with glioblastoma receiving TMZ, according to standard protocol, associated to radiotherapy delivered at 80Gy using SIB-IMRT technic. The first planning target volume (PTV), including oedema and tumour highlighted on T2 flair magnetic resonance imaging (MRI) sequences, will receive 60.8Gy in 32 daily fractions. The second PTV, including tumour highlighted on T1 MRI sequences, will receive 80.0Gy in 32 daily fractions. Secondary objectives are tolerance, survival free progression and quality of live evaluations. Sixty seven patients will be enrolled in this present trial.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03181477
Study type Interventional
Source Centre Georges Francois Leclerc
Contact
Status Active, not recruiting
Phase N/A
Start date April 7, 2017
Completion date September 2, 2025

See also
  Status Clinical Trial Phase
Completed NCT03291977 - Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) Phase 3
Active, not recruiting NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma Phase 1/Phase 2
Terminated NCT03714334 - DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma Phase 1
Recruiting NCT03277638 - Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) Phase 1/Phase 2
Completed NCT03158389 - NCT Neuro Master Match - N²M² (NOA-20) Phase 1/Phase 2
Completed NCT03522298 - Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma Phase 2
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Completed NCT03232424 - NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma Phase 1
Active, not recruiting NCT04116658 - First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma Phase 1/Phase 2
Completed NCT03618667 - GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification Phase 2
Recruiting NCT04128774 - Function and Composition of Regulatory B Cells in Participants With Glioblastoma
Completed NCT03744026 - Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9 Phase 1/Phase 2
Completed NCT04610229 - Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. N/A
Active, not recruiting NCT02974738 - A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) Phase 1
Recruiting NCT03025893 - A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Phase 2/Phase 3
Completed NCT03075514 - Ketogenic Diets as an Adjuvant Therapy in Glioblastoma N/A